The World Health Organization (WHO) prioritizes carbapenem-resistant Enterobacterales (CRE) as one of the top three multidrug-resistant pathogens threatening global health today. In an effort to provide much needed clinical and epidemiological data, researchers designed the CRACKLE-2 study as an observational, multi-center study involving data from 1,040 patients with Centers for Disease Control (CDC) defined CRE.
In addition to providing clinical and whole genome sequencing data for a cohort of CRACKLE-2 study patients, researchers identified a novel subset of CDC-defined CRE. Patient outcomes for infections of all three subsets were similar. This indicates interventional efforts directed only to CPE might be less effective than hoped.